Antibody-Drug-Conjugates as New Therapeutic Modalities for Cancer Therapy - Prof. Dr. Andreas Pahl Chief Executive Officer, Heidelberg Pharma 00:00:00
Professor Andreas Pahl has been Chief Executive Officer of Heidelberg Pharma AG and Managing Director of the subsidiary Heidelberg Pharma Research GmbH since February 2024. Before, he had been Chief Scientific Officer since 2016. Prof. Pahl looks back on 25 years of experience in research and higher education. Prior to his position at Heidelberg Pharma, he was Head of Late Pharmacology at Nycomed and Takeda Pharmaceuticals.
